Merck Provides U.S. and Japan Regulatory Update for Gefapixant

KENILWORTH, N.J.--(BUSINESS WIRE) January 24, 2022 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials